Literature DB >> 28096164

Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.

Brian J Werth1, Laura M Shireman2.   

Abstract

The combination of ampicillin plus ceftaroline has been suggested to be more reliably synergistic against Enterococcus faecalis than ampicillin plus ceftriaxone using time-kill methods. The purpose of this study was to determine if this trend persists in a two-compartment model of simulated endocardial vegetations (SEV) using clinically relevant pharmacokinetic exposures of these antimicrobials. Three clinically derived E. faecalis strains were included in the study. The MICs of study antimicrobials were determined by broth microdilution. Simulations of ampicillin (2 g every 4 h [q4h]; maximum concentration of drug in serum [Cmax], 72.4 mg/liter; half-life [t1/2], 1.9 h), ceftaroline-fosamil (600 mg q8h; Cmax, 21.3 mg/liter; t1/2, 2.66 h), ceftriaxone (Cmax, 257 mg/liter; t1/2, 8 h), and ampicillin plus ceftaroline and ampicillin plus ceftriaxone were evaluated against 3 strains of E. faecalis isolated from patients with endocarditis in an in vitro PK/PD SEV model over 72 h, with a starting inoculum of ∼9 log10 CFU/g. All strains were susceptible to ampicillin (MIC, ≤2 mg/liter). Ceftaroline MICs varied from 2 to 16 mg/liter. All strains had ceftriaxone MICs of 256 mg/liter. W04 and W151 exhibited high-level aminoglycoside resistance but W07 did not. Ampicillin plus ceftaroline resulted in significantly greater reductions in CFU per gram by 72 h than ampicillin for all strains (P ≤ 0.025) than ampicillin plus ceftriaxone for W04 (P = 0.019) but not W07 or W151 (P ≥ 0.15). A 4-fold increase in ampicillin MIC was observed for W07 at 72 h, but this was prevented by the addition of ceftaroline or ceftriaxone. The combination of ampicillin plus ceftaroline appears to be at least as efficacious as ampicillin plus ceftriaxone and may lead to improved activity against some strains of E. faecalis, but these differences may be small and the clinical significance should not be overestimated.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HLAR; PK/PD; ceftriaxone; dual β-lactam; endocarditis; infective endocarditis; synergy

Mesh:

Substances:

Year:  2017        PMID: 28096164      PMCID: PMC5365715          DOI: 10.1128/AAC.02235-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  The combination of ampicillin plus ceftaroline is synergistic against Enterococcus faecalis.

Authors:  Brian J Werth; April N Abbott
Journal:  J Antimicrob Chemother       Date:  2015-05-07       Impact factor: 5.790

2.  Penetration of ampicillin and sulbactam in the lower airways during respiratory infections.

Authors:  Y J Valcke; M T Rosseel; R A Pauwels; M G Bogaert; M E Van der Straeten
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 3.  Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.

Authors:  Louis D Saravolatz; Gary E Stein; Leonard B Johnson
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

4.  Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.

Authors:  Megan K Luther; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 5.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.

Authors:  Larry M Baddour; Walter R Wilson; Arnold S Bayer; Vance G Fowler; Imad M Tleyjeh; Michael J Rybak; Bruno Barsic; Peter B Lockhart; Michael H Gewitz; Matthew E Levison; Ann F Bolger; James M Steckelberg; Robert S Baltimore; Anne M Fink; Patrick O'Gara; Kathryn A Taubert
Journal:  Circulation       Date:  2015-09-15       Impact factor: 29.690

6.  Evaluation of the novel combination of high-dose daptomycin plus trimethoprim-sulfamethoxazole against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus using an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.

Authors:  Molly E Steed; Brian J Werth; Cortney E Ireland; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2012-08-20       Impact factor: 5.191

7.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Authors:  Jordan R Smith; Katie E Barber; Animesh Raut; Mostafa Aboutaleb; George Sakoulas; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2015-02-01       Impact factor: 5.790

8.  Treatment of high-level gentamicin-resistant Enterococcus faecalis endocarditis with daptomycin plus ceftaroline.

Authors:  George Sakoulas; Poochit Nonejuie; Victor Nizet; Joseph Pogliano; Nancy Crum-Cianflone; Fadi Haddad
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

9.  Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance.

Authors:  T Rybkine; J L Mainardi; W Sougakoff; E Collatz; L Gutmann
Journal:  J Infect Dis       Date:  1998-07       Impact factor: 5.226

10.  Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study.

Authors:  C Chirouze; E Athan; F Alla; V H Chu; G Ralph Corey; C Selton-Suty; M-L Erpelding; J M Miro; L Olaison; B Hoen
Journal:  Clin Microbiol Infect       Date:  2013-03-20       Impact factor: 8.067

View more
  5 in total

1.  Meropenem plus Ceftaroline Is Active against Enterococcus faecalis in an In Vitro Pharmacodynamic Model Using Humanized Dosing Simulations.

Authors:  Jaclyn A Cusumano; Kathryn E Daffinee; Emily C Piehl; Mónica García-Solache; Charlene Desbonnet; Louis B Rice; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2022-09-26       Impact factor: 5.938

Review 2.  A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis.

Authors:  Maya Beganovic; Megan K Luther; Louis B Rice; Cesar A Arias; Michael J Rybak; Kerry L LaPlante
Journal:  Clin Infect Dis       Date:  2018-07-02       Impact factor: 9.079

3.  Dual β-Lactam Combinations Highly Active against Mycobacterium abscessus Complex In Vitro.

Authors:  R Pandey; L Chen; C Manca; S Jenkins; L Glaser; C Vinnard; G Stone; J Lee; B Mathema; E L Nuermberger; R A Bonomo; B N Kreiswirth
Journal:  mBio       Date:  2019-02-12       Impact factor: 7.786

Review 4.  Infectious disease: how to manage Gram-positive and Gram-negative pathogen conundrums with dual beta-lactam therapy.

Authors:  Alireza FakhriRavari; Brenda Simiyu; Taylor Morrisette; Yewande Dayo; Jacinda C Abdul-Mutakabbir
Journal:  Drugs Context       Date:  2022-01-20

Review 5.  Anti-biofilm Approach in Infective Endocarditis Exposes New Treatment Strategies for Improved Outcome.

Authors:  Christian Johann Lerche; Franziska Schwartz; Marie Theut; Emil Loldrup Fosbøl; Kasper Iversen; Henning Bundgaard; Niels Høiby; Claus Moser
Journal:  Front Cell Dev Biol       Date:  2021-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.